| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/30/2003 | WO2003008419A1 2-(AMINOMETHYL)-TETRAHYDRO-9-OXA-1,3-DIAZA-CYCLOPENTA[a]NAPHTHALENYL DERIVATIVES WITH ANTIPSYCHOTIC ACTIVITY |
| 01/30/2003 | WO2003008418A1 Imidazo-triazine derivatives as ligands for gaba receptors |
| 01/30/2003 | WO2003008414A1 Chemical compounds |
| 01/30/2003 | WO2003008412A2 Hetero-bicyclic crf antagonists |
| 01/30/2003 | WO2003008410A2 Polypyrroles as agents for treating cancer, treating viral diseases and causing immunosuppression |
| 01/30/2003 | WO2003008407A2 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use |
| 01/30/2003 | WO2003008399A1 Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors |
| 01/30/2003 | WO2003008398A1 Aryl substituted thiazolidinones and the use thereof |
| 01/30/2003 | WO2003008392A1 4-(benzylidene-amino)-3-(methylsulfanyl)-4h-(1, 2, 4) triazin-5-one derivatives having a pde-iv inhibiting and tnf-antagonistic effect for the treatment of cardiac diseases and allergies |
| 01/30/2003 | WO2003008387A1 Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor |
| 01/30/2003 | WO2003008384A1 Substituted 2-thio-3, 5-dicyano-4-phenyl-6-aminopyridines and their use as adenosine receptor-selective ligands |
| 01/30/2003 | WO2003008374A1 Inhibitors of the ice/ced-3 family of cysteine proteases |
| 01/30/2003 | WO2003008371A1 Substituted 4-aminocyclohexanol derivatives |
| 01/30/2003 | WO2003008370A1 Substituted 4-aminocyclohexanols |
| 01/30/2003 | WO2003008365A2 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
| 01/30/2003 | WO2003007993A1 Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor |
| 01/30/2003 | WO2003007977A1 Remedies |
| 01/30/2003 | WO2003007972A1 Agent for the external treatment of pain and skin disorders |
| 01/30/2003 | WO2003007966A1 Active substance combination for medicamentous therapy of nicotine dependency |
| 01/30/2003 | WO2003007963A1 Pyrimidine derivatives and their use in the treatment of neurodegenerative diseases |
| 01/30/2003 | WO2003007958A1 Tetrahydroquinoxalines acting as bradykinin antagonists |
| 01/30/2003 | WO2003007956A1 Treatment for attention-deficit hyperactivity disorder |
| 01/30/2003 | WO2003007954A2 Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors |
| 01/30/2003 | WO2003007950A1 (pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid x receptor modulators |
| 01/30/2003 | WO2003007942A1 Substituted isoindoles and the use thereof |
| 01/30/2003 | WO2003007936A1 Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain |
| 01/30/2003 | WO2003007934A1 Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain |
| 01/30/2003 | WO2003007933A1 Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders |
| 01/30/2003 | WO2003007930A2 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
| 01/30/2003 | WO2003007927A1 Synthesis and functin inhibitors for heat shock proteins |
| 01/30/2003 | WO2003007926A2 Pharmaceutical composition comprising deramciclane for the treatment of the decline and/or damage of cognitive functions |
| 01/30/2003 | WO2003007925A1 Therapeutic strategies for prevention and treatment of alzheimer's disease |
| 01/30/2003 | WO2003007922A2 Pharmaceutical formulation containing an ltb4 antagonist |
| 01/30/2003 | WO2003007912A2 Lyophilized formulation comprising olanzapine |
| 01/30/2003 | WO2003007887A2 Substituted imidazoles as cannabinoid receptor modulators |
| 01/30/2003 | WO2003007880A2 Inhibition of behab cleavage and primary central nervous system (cns) tumors |
| 01/30/2003 | WO2003007876A2 N-fatty acid-amino acid conjugates and therapeutic uses |
| 01/30/2003 | WO2003007875A2 Compounds with analgesic, antipyretic and/or anti-inflammatory activity |
| 01/30/2003 | WO2003007872A2 Process for the preparation of citalopram hydrobromide |
| 01/30/2003 | WO2003007802A2 Pharmaceutical combinations of oxycodone and naloxone |
| 01/30/2003 | WO2003007686A2 Use of copper chelators to inhibit the inactivation of protein c |
| 01/30/2003 | WO2002092088A3 Novel use of 2h-benzimidazol-2-one, 1,3-dihadro-1-(2{4-{3-(trifluoromethyl}phenyl]-1-piperazinyl}ethyl)- and its physiologically acceptable acid addition salts |
| 01/30/2003 | WO2002088079A3 Dual inhibitors of pde 7 and pde 4 |
| 01/30/2003 | WO2002079478A3 Modification of organelle metabolism by a composition comprising unc-51-like kinases, roma1, or 2tm polypeptides and uses thereof for the preration of a medicament for the treatment disorders |
| 01/30/2003 | WO2002059129A3 Substituted tetracyclic pyridoindoles as serotonin agonists and antagonists |
| 01/30/2003 | WO2002057271A3 Thienopyrimidine-based inhibitors of the src family |
| 01/30/2003 | WO2002051435A3 New therapeutic uses of smr1 peptides |
| 01/30/2003 | WO2002043666A3 Compositions containing an antioxidant such as alpha lipoic acid, carnitine, vitamin c or vitamin e for preventing or inhibiting loss of cognitive function |
| 01/30/2003 | WO2002036166A3 Compositions for stimulating cd45 and thereby suppressing microglial activation associated with alzheimer's disease |
| 01/30/2003 | WO2002034243A3 Method for the treatment of neurological and neuropsychological disorders |
| 01/30/2003 | WO2002034242A3 Method for the treatment of neurological and neuropsychological disorders |
| 01/30/2003 | WO2002018583A3 Modified polypeptides stabilized in a desired conformation and methods for producing same |
| 01/30/2003 | WO2002014536A3 Odulating multiple lineage kinase proteins |
| 01/30/2003 | WO2002014356A3 Therapeutic use of a recombinant erythropoietin having high activity and reduced side effects |
| 01/30/2003 | WO2002005795B1 Pharmaceutical combinations for treatment and prevention of diabetes mellitus |
| 01/30/2003 | WO2002003071A3 Modulators of trk protein activity, compositions and uses |
| 01/30/2003 | WO2002002634A3 Human extracellular matrix and cell adhesion polypeptides |
| 01/30/2003 | WO2001093849A3 Treatment of gastroesophageal reflux disease using piperidine derivatives |
| 01/30/2003 | WO2001090359A3 G-protein coupled receptors |
| 01/30/2003 | WO2001081576A3 Novel g protein-coupled receptor con-218 |
| 01/30/2003 | WO2001064877A9 Human schizophrenia gene |
| 01/30/2003 | US20030023997 Transgenic c. elegans as a model organism for investigations on alzheimer's disease |
| 01/30/2003 | US20030023990 Jnk3 modulators and methods of use |
| 01/30/2003 | US20030023117 Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them |
| 01/30/2003 | US20030023104 For prolonging or altering the activity of a compound which is a member of the chlorambucil family |
| 01/30/2003 | US20030023100 For therapy of inflammatory and allergic reactions, drug or alcohol abuse, diarrhoea, gastritis, ulcers, cardiovascular diseases, urinary incontinence, depressions, states of shock, migranes, narcolepsy, overweight, asthma, glaucoma, etc. |
| 01/30/2003 | US20030023098 Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors |
| 01/30/2003 | US20030023085 For therapy and prophylaxis of condition or disorder mediated by a G-protein coupled receptor such as eating disorders, obesity, anxiety disorders and mood disorders |
| 01/30/2003 | US20030023070 For diagnosis, prophylaxis and therapy; therapy of cancer |
| 01/30/2003 | US20030023047 For prevention of influenza virus binding to cells, therapy of schizophrenia and diagnosing chronic viral disease associated with development of cancer |
| 01/30/2003 | US20030023034 p27 (Kip1) -FKBP-12 protein complexes |
| 01/30/2003 | US20030022942 Methods and compositions for treating depression and other disorders using optically pure (-)-bupropion |
| 01/30/2003 | US20030022940 Novel pharmaceutical formulations of modafinil |
| 01/30/2003 | US20030022939 4-Fluoro-N- indan-2-yl benzamide and its use as a pharmaceutical |
| 01/30/2003 | US20030022938 N-fatty acid-amino acid conjugates and therapeutic uses |
| 01/30/2003 | US20030022935 Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents |
| 01/30/2003 | US20030022934 For therapy and prophylaxis of pain and/or neurodegenerative disorders |
| 01/30/2003 | US20030022926 Method for treating neuropathic pain and pharmaceutical preparation therefor |
| 01/30/2003 | US20030022915 Treating obsessive-compulsive disorder, acute stress disorder, post traumatic stress disorder, social anxiety disorder, somatization disorder, specific social phobia, premenstrual dysphoric disorder, and other psychological disorders |
| 01/30/2003 | US20030022914 Nitric oxide synthase inhibitors |
| 01/30/2003 | US20030022909 Use of methylnaltrexone to treat immune suppression |
| 01/30/2003 | US20030022907 Anxiolytic agents and analgesics |
| 01/30/2003 | US20030022904 Pyrazine compounds |
| 01/30/2003 | US20030022901 Serotonergic agents |
| 01/30/2003 | US20030022899 S-6-hydroxy-buspirone |
| 01/30/2003 | US20030022893 Hydroxamic and carboxylic acid derivatives |
| 01/30/2003 | US20030022892 Such as 4-(3-(4-oxo-4,5,6,7-tetrahydroindolon-1-yl)propionylamino) benzoic acid, ethyl ester |
| 01/30/2003 | US20030022890 Heterocyclic dihydropyrimidine compounds |
| 01/30/2003 | US20030022888 Use of mirtazapine for the treatment of sleep disorders |
| 01/30/2003 | US20030022885 Pyrazole compounds useful as protein kinase inhibitors |
| 01/30/2003 | US20030022883 Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one |
| 01/30/2003 | US20030022876 Sustained-release analgesic compounds |
| 01/30/2003 | US20030022875 As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness |
| 01/30/2003 | US20030022873 Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis |
| 01/30/2003 | US20030022866 Analgesic inhibitor of isoforms of cyclic guanosine monophosphate (cGMP)-dependent protein kinase I alpha (PKGI alpha); drug screening |
| 01/30/2003 | US20030022865 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| 01/30/2003 | US20030022836 Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules |
| 01/30/2003 | US20030022830 Methods for enhancing functional recovery following central nervous system ischemia or trauma |
| 01/30/2003 | US20030022822 Novel compounds |
| 01/30/2003 | US20030022813 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels |